Citigroup’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $9.58M | Sell |
75,000
-276,200
| -79% | -$34.5M | ﹤0.01% | 1503 |
|
|
2025
Q4 | $42.8M | Sell |
351,200
-35,500
| -9% | -$4.07M | 0.02% | 695 |
|
|
2025
Q3 | $38.7M | Sell |
386,700
-243,300
| -39% | -$21.9M | 0.02% | 743 |
|
|
2025
Q2 | $52.2M | Buy |
630,000
+265,000
| +73% | +$21.1M | 0.03% | 581 |
|
|
2025
Q1 | $29.6M | Buy |
365,000
+51,100
| +16% | +$4.57M | 0.02% | 784 |
|
|
2024
Q4 | $28.3M | Buy |
+313,900
| New | +$30.4M | 0.02% | 774 |
|
|
2024
Q3 | – | Sell |
-170,000
| Closed | -$15.8M | – | 5814 |
|
|
2024
Q2 | $15.8M | Sell |
170,000
-255,000
| -60% | -$22.9M | 0.01% | 1007 |
|
|
2024
Q1 | $40.3M | Buy |
425,000
+42,500
| +11% | +$3.94M | 0.03% | 579 |
|
|
2023
Q4 | $34.2M | Buy |
382,500
+156,100
| +69% | +$11.6M | 0.02% | 605 |
|
|
2023
Q3 | $16.5M | Buy |
226,400
+48,900
| +28% | +$3.91M | 0.01% | 869 |
|
|
2023
Q2 | $14.8M | Sell |
177,500
-550,000
| -76% | -$46M | 0.01% | 959 |
|
|
2023
Q1 | $55.4M | Buy |
727,500
+650,000
| +839% | +$53.9M | 0.04% | 372 |
|
|
2022
Q4 | $6.43M | Sell |
77,500
-125,000
| -62% | -$10.1M | 0.01% | 1350 |
|
|
2022
Q3 | $16.1M | Sell |
202,500
-527,600
| -72% | -$44.5M | 0.01% | 900 |
|
|
2022
Q2 | $54.2M | Buy |
730,100
+347,000
| +91% | +$26M | 0.04% | 364 |
|
|
2022
Q1 | $34.4M | Buy |
383,100
+230,600
| +151% | +$21.3M | 0.02% | 650 |
|
|
2021
Q4 | $17.1M | Sell |
152,500
-27,500
| -15% | -$3.32M | 0.01% | 1090 |
|
|
2021
Q3 | $22.6M | Buy |
180,000
+20,000
| +13% | +$2.58M | 0.01% | 925 |
|
|
2021
Q2 | $21.7M | Buy |
160,000
+110,000
| +220% | +$14.5M | 0.01% | 950 |
|
|
2021
Q1 | $6.78M | Sell |
50,000
-336,800
| -87% | -$50.4M | ﹤0.01% | 1605 |
|
|
2020
Q4 | $54.5M | Sell |
386,800
-153,800
| -28% | -$19.7M | 0.03% | 501 |
|
|
2020
Q3 | $60.2M | Sell |
540,600
-88,000
| -14% | -$9.87M | 0.04% | 377 |
|
|
2020
Q2 | $70.4M | Sell |
628,600
-579,500
| -48% | -$57.1M | 0.05% | 304 |
|
|
2020
Q1 | $93.6M | Buy |
1,208,100
+103,100
| +9% | +$9.13M | 0.08% | 207 |
|
|
2019
Q4 | $105M | Sell |
1,105,000
-594,200
| -35% | -$51.4M | 0.08% | 240 |
|
|
2019
Q3 | $130M | Buy |
1,699,200
+1,250,600
| +279% | +$104M | 0.1% | 182 |
|
|
2019
Q2 | $39.3M | Sell |
448,600
-26,100
| -5% | -$2.23M | 0.03% | 556 |
|
|
2019
Q1 | $43M | Buy |
474,700
+4,600
| +1% | +$391K | 0.04% | 450 |
|
|
2018
Q4 | $33.7M | Buy |
470,100
+279,600
| +147% | +$22.5M | 0.03% | 552 |
|
|
2018
Q3 | $18.3M | Sell |
190,500
-67,300
| -26% | -$6.52M | 0.02% | 890 |
|
|
2018
Q2 | $24.5M | Sell |
257,800
-169,200
| -40% | -$15.6M | 0.02% | 678 |
|
|
2018
Q1 | $37.5M | Buy |
427,000
+161,000
| +61% | +$14.7M | 0.03% | 497 |
|
|
2017
Q4 | $22.6M | Buy |
266,000
+179,700
| +208% | +$15.1M | 0.02% | 775 |
|
|
2017
Q3 | $7.47M | Sell |
86,300
-67,700
| -44% | -$5.43M | 0.01% | 1433 |
|
|
2017
Q2 | $11.9M | Buy |
154,000
+71,700
| +87% | +$5.09M | 0.01% | 1036 |
|
|
2017
Q1 | $5.71M | Sell |
82,300
-392,300
| -83% | -$26.3M | 0.01% | 1552 |
|
|
2016
Q4 | $28.1M | Buy |
474,600
+229,500
| +94% | +$14.2M | 0.03% | 595 |
|
|
2016
Q3 | $16.2M | Sell |
245,100
-140,800
| -36% | -$8.71M | 0.02% | 800 |
|
|
2016
Q2 | $20.9M | Buy |
385,900
+260,900
| +209% | +$14.3M | 0.02% | 630 |
|
|
2016
Q1 | $6.46M | Buy |
125,000
+46,100
| +58% | +$2.39M | 0.01% | 1336 |
|
|
2015
Q4 | $5.53M | Sell |
78,900
-92,100
| -54% | -$6.28M | 0.01% | 1613 |
|
|
2015
Q3 | $10.6M | Buy |
171,000
+130,500
| +322% | +$10.3M | 0.01% | 1100 |
|
|
2015
Q2 | $3.4M | Buy |
40,500
+19,200
| +90% | +$1.49M | ﹤0.01% | 2082 |
|
|
2015
Q1 | $1.6M | Buy |
+21,300
| New | +$1.49M | ﹤0.01% | 2659 |
|
|
2014
Q4 | – | Sell |
-15,000
| Closed | -$780K | – | 7352 |
|
|
2014
Q3 | $780K | Buy |
+15,000
| New | +$765K | ﹤0.01% | 3193 |
|
|
2014
Q2 | – | Sell |
-15,000
| Closed | -$712K | – | 7337 |
|
|
2014
Q1 | $712K | Buy |
+15,000
| New | +$768K | ﹤0.01% | 3160 |
|
Other funds holding XBI
JFG
Citigroup's XBI Position: Q1 2026 in Review
Citigroup reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 15% in Q1 2026, selling an estimated $233M and leaving 10,663,404 shares worth $1.36B. The position accounts for 0.58% of the portfolio, ranked #27.
Citigroup first reported a position in XBI in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.53B in Q4 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Citigroup held 10,663,404 shares of State Street SPDR S&P Biotech ETF worth $1.36B as of Q1 2026.
- Citigroup sold 1,863,806 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $233M.
- State Street SPDR S&P Biotech ETF made up 0.58% of Citigroup's portfolio in Q1 2026, its #27 holding.
- Citigroup first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 52 quarters since.
- Citigroup's State Street SPDR S&P Biotech ETF position peaked at $1.53B in Q4 2025.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.